Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
暂无分享，去创建一个
M. Cazzola | M. Griesshammer | S. Verstovsek | M. Hino | R. Mesa | A. Vannucchi | V. Rosti | F. Passamonti | C. Harrison | K. Kirito | Carole B. Miller | F. Pane | T. Masszi | S. Durrant | Mark M. Jones | C. Besses | P. Zachée | J. Kiladjian | D. Habr | I. Blau | B. Moiraghi | H. Zhen | Jingjin Li | Nathalie Francillard